Team

Our technical team includes world leading scientists in the field of computational antigen and antibody engineering and experts in immunology and clinical trials of vaccines.

Our executive management has extensive operational experience in the bio-
pharmaceutical industry, including launching and growing companies in the
US and EU, partnering with pharmaceutical companies worldwide, identifying
product and clinical markets and raising US and overseas public and venture
capital funding.


Pascal Brandys

Pascal Brandys is co-founder, Chairman and Chief Executive Officer of CompuVax since inception in 2013. Mr. Brandys has an extensive and successful global experience in the biotechnology industry and international finance.

Previously Mr. Brandys was President and Managing Director of Biobank Technology Ventures LLC, a life science private equity company he co-founded in 2001. Mr. Brandys was also Chairman and CEO of Genset, a genomics company he co-founded in 1989 and grew to a market capitalization of over $1.5 billion before its acquisition by Merck-Serono in 2002. While at Genset Mr. Brandys organized the first dual IPO on NASDAQ and Euronext, structured alliances with seven major pharmaceutical and biotechnology companies, including world’s first pharmacogenomics agreement with Abbott Laboratories in 1997, and expanded operations on four continents, including Australia, California, France, Japan and Singapore. Mr. Brandys has held numerous corporate directorships in public and private companies, most notably NASDAQ listed Innogenetics N.V., ILOG S.A and Ceres, Inc. From 1986 to 1989 Mr. Brandys was a pioneer of biotechnology investments in Europe and Japan as Partner at Eurocontinental Ventures in London and CEO of Unihon Services in Tokyo. Mr. Brandys is a graduate of the Ecole Polytechnique of Paris and holds an MS in Economic Systems from Stanford University. Mr. Brandys was also a founder and President of France Biotech, the professional association of French biotechnology companies from 1997 to 2000 and he received the Outstanding Service to Biotechnology Award from the European Life Sciences Partnering Foundation in 1999.

William Schief

PhD is co-founder, Director and Chief Scientific Officer of CompuVax since inception in 2013. Dr. Schief is a physicist, computational structural biologist and protein engineer who has developed the key immunogen design methods and immunogen molecules forming the scientific basis for CompuVax.

The Schief laboratory develops novel antigens, immunogens, and immunization regimens specifically tailored to focus antibody immune responses on particular epitopes. They use a highly multi-disciplinary computational and experimental approach, wielding the tools of computational structural biology, in vitro evolution (such as yeast cell surface display), biophysics, bioengineering and immunology, in their vaccine development efforts. Dr. Schief pioneered the computational methods of scaffolding, remodeling, and resurfacing, as well as the integration of computational design with in vitro evolution for immunogen design. The Schief lab is developing methods for oriented, multivalent display of designed immunogens to further focus and magnify epitope-specific responses. Dr. Schief has a BS in Applied Mathematics from Yale University and a PhD in Physics from the University of Washington. He is currently an Associate Professor of Immunology at The Scripps Research Institute and a Principal Scientist at the International AIDS Vaccine Initiative.

James Crowe

MD is the Immunology Advisor of CompuVax since 2014. Dr. Crowe is an immunologist and board-certified infectious diseases specialist. He is Professor of Pediatrics, Pathology, Microbiology and Immunology, Ann Scott Carell Chair, and Director of the Vanderbilt Vaccine Center.

His laboratory has a broad portfolio of work in the area of viral immunology and cell biology, with an aim to discovery of mechanisms important to development of new vaccines. He is an elected member of the Institute of Medicine of the National Academies and Fellow of the American Association for the Advancement of Science, the American Academy of Microbiology, American Society for Clinical Investigation, AAP, IDSA, APS and other elected societies. His work has been published in over 180 publications in high-quality journals including Cell, Nature, Science, Nature Medicine, Proceedings of the National Academy of Sciences USA, the New England Journal of Medicine, and JAMA. He has been the recipient of investigator awards from the March of Dimes, American Society for Microbiology, Pediatric Infectious Diseases Society, and Society for Pediatric Research. He was awarded the Judson Daland Prize of the American Philosophical Society, the Oswald Avery Award of the IDSA, the E. Mead Johnson Award for Excellence in Pediatrics, the 2007 Outstanding Investigator Award of the American Federation for Medical Research and the 2010 Norman J. Siegel Award of the American Pediatric Society. Dr. Crowe received his MD degree from the University of NC at Chapel Hill, where he also did his pediatrics residency. Following his clinical training, he received five years of postdoctoral training in the Laboratory of Infectious Diseases at the NIH.

Philip Johnson

MD is the Medical and Clinical Advisor of CompuVax since 2016. Dr. Johnson is a virologist and is board-certified in infectious diseases. He currently serves as Senior Advisor to the International AIDS Vaccine Initiative.

Dr. Johnson’s earliest research focused on the characterization of systemic and local immune responses in children immunized with live attenuated influenza vaccines. He then went on to work with Peter Collins at the NIH on the molecular characterization of respiratory syncytial viruses (RSV). In more recent years, his laboratory has emphasized development of gene transfer technology for use in prophylactic vaccines. Vaccines developed in his lab have been tested in phase 1 and 2 human clinical trials in four countries. In the last few years, Dr. Johnson pioneered the use of recombinant adeno-associated virus vectors to deliver genes encoding for neutralizing antibodies that inhibit HIV entry as a novel approach to a prophylactic HIV vaccine. A phase 1 human clinical trial testing this approach is currently underway in Europe.
Dr. Johnson received his undergraduate and medical degrees from the University of North Carolina, followed by pediatric residency and infectious diseases fellowship at Vanderbilt University. After fellowship training, he worked at the NIH and Nationwide Children's Hospital for 20 years before assuming the role of Chief Scientific Officer and Executive Vice President at the Children’s Hospital of Philadelphia from 2005 - 2015. Dr. Johnson was also a Professor in the Department of Pediatrics at the University of Pennsylvania Perelman School of Medicine and held the Edmond F. Notebaert Chair in Pediatric Research. He has received several national honors including election to the American Pediatric Society and being named a Fellow of the American Association for the Advancement of Science and a Fellow of the American Academy of Microbiology.